 Nathan Belliveau
Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Escherichia coli | 6 | 2021 | 835 | 1.260 |
Why?
| | Cell Movement | 3 | 2026 | 963 | 0.850 |
Why?
| | Neutrophils | 3 | 2026 | 1127 | 0.780 |
Why?
| | Promoter Regions, Genetic | 5 | 2024 | 1247 | 0.710 |
Why?
| | Leukocytes | 1 | 2023 | 296 | 0.700 |
Why?
| | Genome, Bacterial | 2 | 2020 | 123 | 0.670 |
Why?
| | Gene Expression Regulation, Bacterial | 3 | 2020 | 337 | 0.620 |
Why?
| | Green Fluorescent Proteins | 2 | 2020 | 407 | 0.620 |
Why?
| | Membrane Proteins | 1 | 2026 | 1166 | 0.600 |
Why?
| | Escherichia coli Proteins | 2 | 2020 | 201 | 0.510 |
Why?
| | Proteomics | 1 | 2021 | 1188 | 0.410 |
Why?
| | Sequence Analysis, DNA | 2 | 2020 | 778 | 0.250 |
Why?
| | Electricity | 1 | 2026 | 26 | 0.240 |
Why?
| | Arabidopsis Proteins | 1 | 2024 | 76 | 0.200 |
Why?
| | Arabidopsis | 1 | 2024 | 94 | 0.200 |
Why?
| | Binding Sites | 4 | 2020 | 1311 | 0.200 |
Why?
| | Actin Cytoskeleton | 1 | 2023 | 103 | 0.190 |
Why?
| | Microfluidics | 2 | 2014 | 61 | 0.180 |
Why?
| | Models, Biological | 2 | 2020 | 1764 | 0.180 |
Why?
| | Nanoparticles | 3 | 2014 | 517 | 0.180 |
Why?
| | Allosteric Regulation | 2 | 2019 | 99 | 0.170 |
Why?
| | Cell Size | 1 | 2021 | 93 | 0.170 |
Why?
| | Gene Expression Regulation | 3 | 2019 | 2601 | 0.170 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2024 | 414 | 0.160 |
Why?
| | V(D)J Recombination | 1 | 2020 | 8 | 0.160 |
Why?
| | Protein Sorting Signals | 1 | 2020 | 21 | 0.160 |
Why?
| | Receptors, Antigen | 1 | 2020 | 15 | 0.160 |
Why?
| | Gene Regulatory Networks | 2 | 2020 | 318 | 0.160 |
Why?
| | Genes, Switch | 1 | 2020 | 6 | 0.160 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 638 | 0.160 |
Why?
| | HL-60 Cells | 1 | 2020 | 30 | 0.160 |
Why?
| | Saccharomyces cerevisiae | 1 | 2024 | 574 | 0.160 |
Why?
| | Epithelial Cells | 1 | 2026 | 1135 | 0.150 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 452 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2019 | 371 | 0.130 |
Why?
| | Actins | 1 | 2020 | 426 | 0.130 |
Why?
| | Nucleic Acid Conformation | 1 | 2020 | 724 | 0.130 |
Why?
| | Lipids | 2 | 2012 | 707 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 372 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 560 | 0.120 |
Why?
| | Cell Differentiation | 1 | 2023 | 2050 | 0.110 |
Why?
| | Bacteria | 1 | 2021 | 766 | 0.110 |
Why?
| | Models, Genetic | 1 | 2018 | 527 | 0.110 |
Why?
| | Gene Expression | 1 | 2019 | 1478 | 0.100 |
Why?
| | Computational Biology | 1 | 2019 | 669 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2019 | 935 | 0.100 |
Why?
| | Phosphatidylcholines | 1 | 2014 | 131 | 0.100 |
Why?
| | Androgen Receptor Antagonists | 1 | 2012 | 35 | 0.090 |
Why?
| | Cholesterol | 1 | 2014 | 408 | 0.090 |
Why?
| | Phenotype | 1 | 2019 | 3170 | 0.080 |
Why?
| | Receptors, Androgen | 1 | 2012 | 149 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 381 | 0.080 |
Why?
| | Mutation | 1 | 2019 | 4090 | 0.070 |
Why?
| | Animals | 3 | 2026 | 38106 | 0.060 |
Why?
| | Co-Repressor Proteins | 1 | 2024 | 18 | 0.050 |
Why?
| | Histone Chaperones | 1 | 2024 | 15 | 0.050 |
Why?
| | Transcription Initiation, Genetic | 1 | 2024 | 19 | 0.050 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2024 | 54 | 0.050 |
Why?
| | Transcriptional Elongation Factors | 1 | 2024 | 39 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 981 | 0.050 |
Why?
| | Signal Transduction | 1 | 2018 | 5226 | 0.050 |
Why?
| | Humans | 5 | 2026 | 145785 | 0.050 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2024 | 130 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2020 | 1454 | 0.050 |
Why?
| | DNA | 2 | 2019 | 1437 | 0.050 |
Why?
| | Particle Size | 2 | 2014 | 381 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2024 | 429 | 0.040 |
Why?
| | Algorithms | 2 | 2019 | 1851 | 0.040 |
Why?
| | DNA Cleavage | 1 | 2020 | 7 | 0.040 |
Why?
| | Ribonucleosides | 1 | 2020 | 7 | 0.040 |
Why?
| | Pentosyltransferases | 1 | 2020 | 7 | 0.040 |
Why?
| | Xanthines | 1 | 2020 | 23 | 0.040 |
Why?
| | Stochastic Processes | 1 | 2020 | 65 | 0.040 |
Why?
| | Single Molecule Imaging | 1 | 2020 | 45 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 80 | 0.040 |
Why?
| | Vertebrates | 1 | 2020 | 63 | 0.040 |
Why?
| | Lac Repressors | 1 | 2019 | 1 | 0.040 |
Why?
| | Operator Regions, Genetic | 1 | 2019 | 8 | 0.040 |
Why?
| | Membrane Transport Proteins | 1 | 2020 | 154 | 0.040 |
Why?
| | Gene Dosage | 1 | 2019 | 145 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 424 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 145 | 0.040 |
Why?
| | Lymphocytes | 1 | 2020 | 376 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2019 | 507 | 0.030 |
Why?
| | Trans-Activators | 1 | 2020 | 396 | 0.030 |
Why?
| | Genome | 1 | 2019 | 305 | 0.030 |
Why?
| | Thermodynamics | 1 | 2018 | 419 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1599 | 0.020 |
Why?
| | Drug Compounding | 1 | 2014 | 107 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2240 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2805 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1482 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1736 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 887 | 0.020 |
Why?
| | Triglycerides | 1 | 2012 | 520 | 0.020 |
Why?
| | Water | 1 | 2012 | 448 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 936 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1450 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2865 | 0.010 |
Why?
| | Male | 1 | 2012 | 73012 | 0.000 |
Why?
|
|
Belliveau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|